MedTrace Logo

The Study of Pharmacokinetics and Pharmacodynamics of Huperzine a Injection in Healthy Chinese Subjects

NCT06570655 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-12-19

No results posted yet for this study

Summary

The study used a single-center, open, sequential single-dose design. To evaluate the pharmacokinetics and dose-exposure relationship of huperzine A injection

Conditions

  • Healthy Subjects

Interventions

DRUG

Huperzine A injection

intramuscular

DRUG

Huperzine A injection

intravenous bolus

Sponsors & Collaborators

  • Zhejiang Hospital

    collaborator OTHER

  • Wanbangde Pharmaceutical Group Co., LTD

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-16
Primary Completion
2024-06-20
Completion
2024-08-29

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06570655 on ClinicalTrials.gov